Canopy Biosciences Develops Spatial Proteomics Assay for COVID-19

ST. LOUIS, Missouri ─ May 19, 2021 ─ Canopy Biosciences, a Bruker Company, today announced the successful development of a new assay for examining immune response to COVID-19. The assay uses high-plex spatial proteomics and is performed on Canopy’s ZellScannerONE precise spatial phenotyping instrument. ZellScannerONE enables multiplexed spatial quantification of protein biomarkers in tissue samples, as well as in suspended cells. Relative to traditional techniques, such as flow cytometry, Canopy’s ChipCytometry is able to detect and quantify many more markers with spatial resolution and longer storage times.

The COVID-19 Immune Response Assay will be available initially as a service, performed by Canopy on researcher-supplied samples, and a reagent kit will be available at a later date. The COVID-19 Immune Response Assay allows researchers to spatially profile 18 different protein biomarkers. Data from these markers further enables the identification and quantification of 32 distinct cellular phenotypes, including major immune cell types as well as various cell states (e.g., exhaustion, activation, and proliferation). Using the COVID-19 Immune Response Assay on peripheral blood mononuclear cells (PBMCs), Canopy was able to characterize differences in immune cell composition in healthy patients versus those with severe COVID-19, consistent with previous reports.

“The power of the COVID-19 Immune Response Assay is that it enables researchers to examine immune response in the absence of freeze-thaw artifacts that are inherent in traditional techniques, such as flow cytometry. Because the samples are stored stably on ZellSafe microfluidic chips, they can be assayed up to two years after collection. Additionally, the non-destructive nature of the assay allows samples to be reinterrogated with additional markers at a later date,” said Thomas Campbell, Ph.D., Product Manager at Canopy. “As a microscopy-based technique, researchers can also actually visualize the 18-plex biomarkers in addition to quantifying immune cell populations through well characterized gating strategies. This adds a layer of confidence and precision not available using traditional techniques.”

The COVID-19 Immune Response Assay is available for service projects immediately. For more information on the new assay, visit https://canopybiosciences.com/18-plex-covid-19-immune-cell-phenotyping/.

The COVID-19 Immune Response Panel reveals significant differences in the immune response of COVID-19 patients as compared to healthy control patients

About ZellScannerONE

The ZellScannerONE instrument is a fully integrated automated imaging system that enables quantitative measurements of high-plex protein biomarker assays across a range of sample types (e.g., tissue specimens, PBMCs, etc.). Using sequential staining and photobleaching on ZellSafe microfluidic chips, a virtually unlimited number of biomarkers can be visualized and quantified. The ZellScannerONE produces high-resolution, high-dynamic-range (HDR) images that are analyzed by powerful AI-driven software to quantify protein targets with true single-cell resolution.

About Canopy Biosciences, a Bruker Company

Canopy Biosciences was formed in 2016 and rapidly built a comprehensive portfolio of products and services for spatial biology, multi-omics, and bioprocessing. Canopy’s technologies include precise spatial multiplexing in cells and tissue samples via the ZellScanner platform, ultrasensitive DNA sequencing (RareSeq), RNA-Seq, and gene expression analysis. Canopy Biosciences is headquartered in St. Louis, Missouri, with additional CRO sites in California and Germany to serve researchers at universities, research institutions, and biotechnology and pharmaceutical companies worldwide. Canopy was acquired by Bruker Corporation (Nasdaq: BRKR) in 2020. Additional information is available at www.canopybiosciences.com.